<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7462898\results\search\testTrace\results.xml">
  <result pre="specific anti-viral therapy and vaccines that are being developed for" exact="treatment" post="and prevention of COVID-19. Abstract Coronavirus disease-19 (COVID-19) is"/>
  <result pre="of the virus and its modus operandi for replication and" exact="infection" post="of the host cells have been reasonably well-characterized. This"/>
  <result pre="secretory vesicles. The excess load of the viral proteins during" exact="infection" post="with SARS-CoV-2 could overwhelm the ER leading to ER"/>
  <result pre="are collectively responsible for part of the phenotypic effects of" exact="infection" post="with SARS-CoV-2. Fig. 1 Various steps (numbered) involved in"/>
  <result pre="ability to replicate effectively by copying the viral RNA, evading" exact="detection" post="by the host-immune system, and destroying the host-defenses (reviewed"/>
  <result pre="proteases on the same cell type is considered essential for" exact="infection" post="with SARS-CoV-2. Data in the Human Protein Atlas (https://www.proteinatlas.org/)"/>
  <result pre="or harmful effects of induction of interferons in response to" exact="infection" post="with SARS-CoV-2 [14]. TMPRSS2 is expressed in the alveolar"/>
  <result pre="through exocytosis. 4 A primer on host-immune response to SARS-CoV-2" exact="infection" post="SARS viruses utilize a number of mechanisms to evade"/>
  <result pre="infection SARS viruses utilize a number of mechanisms to evade" exact="detection" post="by the host-immune response, including suppression of host interferon"/>
  <result pre="[24]. It is less (about 3.5%) in those diagnosed by" exact="testing" post="alone (reverse-transcriptase polymerase chain testing alone), which includes symptomatic"/>
  <result pre="3.5%) in those diagnosed by testing alone (reverse-transcriptase polymerase chain" exact="testing" post="alone), which includes symptomatic and asymptomatic individuals. The overall"/>
  <result pre="of the elderly to COVID-19, in addition to the high" exact="prevalence" post="of co-morbid conditions, such as the presence of underlying"/>
  <result pre="and others. Although males and females are equally susceptible to" exact="infection" post="with SARS-CoV-2, there is a sex-dependent difference in the"/>
  <result pre="COVID-19. Whether these changes are the direct consequence of viral" exact="infection" post="or are secondary to increased levels of cytokines, catecholamines,"/>
  <result pre="researchers to test the existing compounds and to perform large-scale" exact="screening" post="to identify new compounds that effectively target the specific"/>
  <result pre="the epigenetic modulator JQ1 to medicinal herbs, in prevention and" exact="treatment" post="of COVID-19 (https://clinicaltrials.gov/). In the following sections, a selected"/>
  <result pre="as convalescent plasma, containing neutralizing antibodies, has been used for" exact="treatment" post="of infectious diseases for decades. A neutralizing antibody functions"/>
  <result pre="convalescent plasma from COVID-19 patients as a â€œmay be effectiveâ€�" exact="treatment" post="in hospitalized patients with COVID-19. 6.1.3 TMPRSS2 inhibitors The"/>
  <result pre="data in mice show that deletion of Tmprss2 gene abrogates" exact="infection" post="with viruses similar to SARS-CoV-2 [48]. Camostat mesylate and"/>
  <result pre="which are commercially available and are currently being used for" exact="treatment" post="of chronic pancreatitis and cystic fibrosis, respectively. Preclinical studies"/>
  <result pre="of chronic pancreatitis and cystic fibrosis, respectively. Preclinical studies show" exact="treatment" post="with camostat mesylate blocks entry of SARS-CoV-2 into the"/>
  <result pre="efficacy of camostat and the more potent nafamostat in the" exact="treatment" post="of patients with COVID-19 is being tested in several"/>
  <result pre="of hydroxychloroquine (alone or in combination with azithromycin) in the" exact="treatment" post="of patients with COVID-19 has been dampened in the"/>
  <result pre="randomized clinical trials [52]. There were no beneficial effects of" exact="treatment" post="with hydroxychloroquine in the Randomised Evaluation of COVID-19 Therapy"/>
  <result pre="are still ongoing to test efficacy of hydroxychloroquine in the" exact="treatment" post="of patients with COVID-19. Table 1 Results of randomized"/>
  <result pre="of nucleoside analogues, which were initially developed and approved for" exact="treatment" post="of other viral diseases, such as Ebola virus disease"/>
  <result pre="analogues, remdesivir, an adenosine analogue, which was originally developed for" exact="treatment" post="of Ebola virus disease, has been approved by FDA"/>
  <result pre="[60,61]. Several randomized clinical trials (Phase 2 and 3) are" exact="testing" post="efficacy of favipiravir in hospitalized patients with COVID-19. EIDD-2801"/>
  <result pre="of a protease inhibitor and P450 inhibitor, respectively, used for" exact="treatment" post="of HIV, is also candidate to inhibit SARS-CoV-2 proteases"/>
  <result pre="UK (https://www.recoverytrial.net/results/lopinavar-results), which included 1,596 hospitalized patients in the lopinavir/ritonavir" exact="treatment" post="group and 3,376 patients in the usual care group,"/>
  <result pre="reverse, in part, the response of the host cells to" exact="infection" post="with SARS-CoV-2. A notable phenotypic feature of COVID-19 is"/>
  <result pre="tocilizumab, a monoclonal antibody against IL6, have been used in" exact="treatment" post="of patients with COVID-19. Preliminary observational data show that"/>
  <result pre="treatment of patients with COVID-19. Preliminary observational data show that" exact="treatment" post="with tocilizumab is associated with improved laboratory and clinical"/>
  <result pre="was fully sequenced within a month or two after its" exact="isolation" post="[2]. In addition, building on the knowledge gained from"/>
  <result pre="coined the term vaccination. The virus is typically inactivated upon" exact="treatment" post="with formalin or other chemicals or upon exposure to"/>
  <result pre="response, as evidenced by decreased viral load and protection against" exact="infection" post="upon challenge of the monkey with SARS-CoV-2 [82]. Inactivated"/>
  <result pre="chemical libraries to find suitable compounds, followed by optimization and" exact="testing" post="in preclinical and phase 1-3 clinical trials. At the"/>
  <result pre="and the cardiovascular system: implications for risk assessment, diagnosis, and" exact="treatment" post="optionsCardiovasc Res11620201666168732352535 18Del ValleDMKim-SchulzeSHsin-HuiHBeckmannNDNirenbergSWangBAn inflammatory cytokine signature helps predict"/>
  <result pre="print). 22SnyderTMGittelmanRMKlingerMMayDHOsborneEJTaniguchiRMagnitude and dynamics of the T-cell response to SARS-CoV-2" exact="infection" post="at both individual and population levelsmedRxiv.2020, 2020.07.31.20165647 23NguyenADavidJKMadenSKWoodMAWeederBRNelloreAHuman leukocyte"/>
  <result pre="the split-protein-based cell-cell fusion assayAntimicrob Agents Chemother6020166532653927550352 50JangSRheeJY.Three cases of" exact="treatment" post="with nafamostat in elderly patients with COVID-19 pneumonia who"/>
  <result pre="coronaviruses that cause SARS and COVID-19Antiviral Res1802020104857 56BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACRemdesivir for the" exact="treatment" post="of Covid-19 - preliminary reportN Engl J Med38310202099432649078 57WangYZhangDDuGDuRZhaoJJinYRemdesivir"/>
  <result pre="severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet39520201569157832423584 58AntinoriSCossuMVRidolfoALRechRBonazzettiCPaganiGCompassionate remdesivir" exact="treatment" post="of severe Covid-19 pneumonia in intensive care unit (ICU)"/>
  <result pre="patients with moderate COVID-19: a randomized clinical trialJAMA2020, e2016349 60CaiQYangMLiuDChenJShuDXiaJExperimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control studyEngineering (Beijing)2020"/>
  <result pre="of coronavirus disease 2019 (COVID-19) in ChinaJ Infect Dis2225202074675432563194 66XuXHanMLiTSunWWangDFuBEffective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
 </snippets>
</snippetsTree>
